Background: Amplified copy number in the plasmepsin II/III genes within Plasmodium falciparum has been associated with decreased sensitivity to piperaquine. To examine this association and test whether additional loci might also contribute, we performed a genome-wide association study of ex vivo P. falciparum susceptibility to piperaquine. Methods: Plasmodium falciparum DNA from 183 samples collected primarily from Cambodia was genotyped at 33716 genome-wide single nucleotide polymorphisms (SNPs). Linear mixed models and random forests were used to estimate associations between parasite genotypes and piperaquine susceptibility. Candidate polymorphisms were evaluated for their association with dihydroartemisinin-piperaquine treatment outcomes in an independent dataset. Results: Single nucleotide polymorphisms on multiple chromosomes were associated with piperaquine 90% inhibitory concentrations (IC90) in a genome-wide analysis. Fine-mapping of genomic regions implicated in genome-wide analyses identified multiple SNPs in linkage disequilibrium with each other that were significantly associated with piperaquine IC90, including a novel mutation within the gene encoding the P. falciparum chloroquine resistance transporter, PfCRT. This mutation (F145I) was associated with dihydroartemisinin-piperaquine treatment failure after adjusting for the presence of amplified plasmepsin II/III, which was also associated with decreased piperaquine sensitivity. Conclusions: Our data suggest that, in addition to plasmepsin II/III copy number, other loci, including pfcrt, may also be involved in piperaquine resistance.
Background: Amplified copy number in the plasmepsin II/III genes within Plasmodium falciparum has been associated with decreased sensitivity to piperaquine. To examine this association and test whether additional loci might also contribute, we performed a genome-wide association study of ex vivo P. falciparum susceptibility to piperaquine. Methods:Plasmodium falciparum DNA from 183 samples collected primarily from Cambodia was genotyped at 33716 genome-wide single nucleotide polymorphisms (SNPs). Linear mixed models and random forests were used to estimate associations between parasite genotypes and piperaquine susceptibility. Candidate polymorphisms were evaluated for their association with dihydroartemisinin-piperaquine treatment outcomes in an independent dataset. Results: Single nucleotide polymorphisms on multiple chromosomes were associated with piperaquine 90% inhibitory concentrations (IC90) in a genome-wide analysis. Fine-mapping of genomic regions implicated in genome-wide analyses identified multiple SNPs in linkage disequilibrium with each other that were significantly associated with piperaquine IC90, including a novel mutation within the gene encoding the P. falciparumchloroquine resistance transporter, PfCRT. This mutation (F145I) was associated with dihydroartemisinin-piperaquine treatment failure after adjusting for the presence of amplified plasmepsin II/III, which was also associated with decreased piperaquine sensitivity. Conclusions: Our data suggest that, in addition to plasmepsin II/III copy number, other loci, including pfcrt, may also be involved in piperaquine resistance.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda Journal: N Engl J Med Date: 2008-12-08 Impact factor: 91.245
Authors: Christian M Parobek; Jessica T Lin; David L Saunders; Eric J Barnett; Chanthap Lon; Charlotte A Lanteri; Sujata Balasubramanian; Nicholas Brazeau; Derrick K DeConti; Deen L Garba; Steven R Meshnick; Michele D Spring; Char Meng Chuor; Jeffrey A Bailey; Jonathan J Juliano Journal: Proc Natl Acad Sci U S A Date: 2016-11-28 Impact factor: 11.205
Authors: Daria Van Tyne; Daniel J Park; Stephen F Schaffner; Daniel E Neafsey; Elaine Angelino; Joseph F Cortese; Kayla G Barnes; David M Rosen; Amanda K Lukens; Rachel F Daniels; Danny A Milner; Charles A Johnson; Ilya Shlyakhter; Sharon R Grossman; Justin S Becker; Daniel Yamins; Elinor K Karlsson; Daouda Ndiaye; Ousmane Sarr; Souleymane Mboup; Christian Happi; Nicholas A Furlotte; Eleazar Eskin; Hyun Min Kang; Daniel L Hartl; Bruce W Birren; Roger C Wiegand; Eric S Lander; Dyann F Wirth; Sarah K Volkman; Pardis C Sabeti Journal: PLoS Genet Date: 2011-04-21 Impact factor: 5.917
Authors: Olivo Miotto; Jacob Almagro-Garcia; Magnus Manske; Bronwyn Macinnis; Susana Campino; Kirk A Rockett; Chanaki Amaratunga; Pharath Lim; Seila Suon; Sokunthea Sreng; Jennifer M Anderson; Socheat Duong; Chea Nguon; Char Meng Chuor; David Saunders; Youry Se; Chantap Lon; Mark M Fukuda; Lucas Amenga-Etego; Abraham V O Hodgson; Victor Asoala; Mallika Imwong; Shannon Takala-Harrison; François Nosten; Xin-Zhuan Su; Pascal Ringwald; Frédéric Ariey; Christiane Dolecek; Tran Tinh Hien; Maciej F Boni; Cao Quang Thai; Alfred Amambua-Ngwa; David J Conway; Abdoulaye A Djimdé; Ogobara K Doumbo; Issaka Zongo; Jean-Bosco Ouedraogo; Daniel Alcock; Eleanor Drury; Sarah Auburn; Oliver Koch; Mandy Sanders; Christina Hubbart; Gareth Maslen; Valentin Ruano-Rubio; Dushyanth Jyothi; Alistair Miles; John O'Brien; Chris Gamble; Samuel O Oyola; Julian C Rayner; Chris I Newbold; Matthew Berriman; Chris C A Spencer; Gilean McVean; Nicholas P Day; Nicholas J White; Delia Bethell; Arjen M Dondorp; Christopher V Plowe; Rick M Fairhurst; Dominic P Kwiatkowski Journal: Nat Genet Date: 2013-04-28 Impact factor: 38.330
Authors: Huynh Hong Quang; Marina Chavchich; Nguyen Thi Minh Trinh; Kimberly A Edgel; Michael D Edstein; Nicholas J Martin Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191
Authors: Megan R Ansbro; Zina Itkin; Lu Chen; Gergely Zahoranszky-Kohalmi; Chanaki Amaratunga; Olivo Miotto; Tyler Peryea; Charlotte V Hobbs; Seila Suon; Juliana M Sá; Arjen M Dondorp; Rob W van der Pluijm; Thomas E Wellems; Anton Simeonov; Richard T Eastman Journal: ACS Pharmacol Transl Sci Date: 2020-11-02